Insmed Company Profile (NASDAQ:INSM)

About Insmed (NASDAQ:INSM)

Insmed logoInsmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSM
  • CUSIP: N/A
  • Web:
  • Market Cap: $751.64 million
  • Outstanding Shares: 62,378,000
Average Prices:
  • 50 Day Moving Avg: $15.73
  • 200 Day Moving Avg: $16.31
  • 52 Week Range: $10.21 - $19.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.55
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.34 per share
  • Price / Book: 8.99
  • EBIDTA: ($180,870,000.00)
  • Return on Equity: -130.41%
  • Return on Assets: -85.48%
  • Debt-to-Equity Ratio: 0.66%
  • Current Ratio: 3.67%
  • Quick Ratio: 3.67%
  • Average Volume: 462,953 shs.
  • Beta: 0.67
  • Short Ratio: 8.96

Frequently Asked Questions for Insmed (NASDAQ:INSM)

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.09. View Insmed's Earnings History.

Where is Insmed's stock going? Where will Insmed's stock price be in 2017?

6 brokerages have issued twelve-month price objectives for Insmed's stock. Their predictions range from $17.00 to $28.00. On average, they anticipate Insmed's stock price to reach $23.80 in the next twelve months. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:

  • William H. Lewis, President, Chief Executive Officer, Director
  • Paolo Tombesi, Chief Financial Officer
  • S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
  • Walter Perkins Ph.D., Chief Technology Officer
  • Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
  • Mark Quigley, Vice President- Quality Assurance
  • Christine A. Pellizzari, General Counsel, Corporate Secretary
  • Roger Adsett, Chief Commercial Officer
  • Paul Streck, Chief Medical Officer
  • Donald J. Hayden Jr., Non-Executive Chairman of the Board

Who owns Insmed stock?

Insmed's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Palo Alto Investors LLC (9.01%), Vanguard Group Inc. (6.17%), State Street Corp (2.77%), Janus Henderson Group PLC (2.64%) and Emerald Advisers Inc. PA (2.07%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden, Jr, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.

Who sold Insmed stock? Who is selling Insmed stock?

Insmed's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Goldman Sachs Group Inc., AXA, TD Asset Management Inc., Ameriprise Financial Inc., California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC. and ProShare Advisors LLC. Company insiders that have sold Insmed stock in the last year include Andrew T Drechsler, Myrtle S Potter and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.

Who bought Insmed stock? Who is buying Insmed stock?

Insmed's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Emerald Advisers Inc. PA, State Street Corp, Emerald Mutual Fund Advisers Trust, Nexthera Capital LP, Chartwell Investment Partners LLC, Palo Alto Investors LLC and Vanguard Group Inc.. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed.

How do I buy Insmed stock?

Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of Insmed stock can currently be purchased for approximately $12.05.

MarketBeat Community Rating for Insmed (NASDAQ INSM)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insmed (NASDAQ:INSM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $23.80 (97.51% upside)

Analysts' Ratings History for Insmed (NASDAQ:INSM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$28.00MediumView Rating Details
8/2/2017HC WainwrightReiterated RatingBuyMediumView Rating Details
7/10/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$23.00MediumView Rating Details
6/11/2017Citigroup Inc.Reiterated RatingNeutral$14.00 -> $17.00HighView Rating Details
5/1/2017Stifel NicolausBoost Price TargetBuy$23.00 -> $27.00MediumView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
4/17/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
2/26/2016Leerink SwannLower Price TargetOutperform$29.00 -> $23.00N/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Insmed (NASDAQ:INSM)
Earnings by Quarter for Insmed (NASDAQ:INSM)
Earnings History by Quarter for Insmed (NASDAQ INSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.63)($0.72)ViewListenView Earnings Details
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.10)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insmed (NASDAQ:INSM)
2017 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.58)($0.58)($0.58)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)


Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insmed (NASDAQ:INSM)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 92.63%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Christine A PellizzariGeneral CounselBuy10,000$15.14$151,400.00View SEC Filing  
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.00View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.14View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.00View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.30View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insmed (NASDAQ:INSM)
Latest Headlines for Insmed (NASDAQ:INSM)
DateHeadline logoEvercore ISI Initiates Coverage on Insmed, Inc. (INSM) - August 16 at 6:26 PM logoSee what the IHS Markit Score report has to say about Insmed Inc. - August 9 at 8:13 PM logoAre Options Traders Betting on a Big Move in Insmed (INSM) Stock? - August 9 at 8:13 PM logoInsmed, Inc. (NASDAQ:INSM) Downgraded to Sell at BidaskClub - August 5 at 7:26 PM logoForm 8-K INSMED Inc For: Aug 03 - - August 5 at 6:44 PM logoEdited Transcript of INSM earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 4 at 1:03 AM logoBRIEF-Insmed reports Q2 loss per share $0.72 - August 3 at 8:03 PM logoInsmed Reports Second Quarter 2017 Financial Results and Provides Business Update - August 3 at 8:03 PM logoInsmed reports 2Q loss - August 3 at 8:03 PM logoInsmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Brokerages - August 1 at 8:01 AM logoInsmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017 - July 27 at 11:00 PM logo-$0.63 EPS Expected for Insmed, Inc. (NASDAQ:INSM) This Quarter - July 26 at 8:22 AM logoImplied Volatility Surging For Insmed, Inc. (INSM) Stock Options - Nasdaq - July 18 at 2:23 AM logoZacks Investment Research Downgrades Insmed, Inc. (INSM) to Hold - July 18 at 12:26 AM logoImplied Volatility Surging For Insmed, Inc. (INSM) Stock Options - July 17 at 8:24 AM logoInsmed to Host Analyst and Investor Day on July 19, 2017 - July 13 at 3:20 AM logoInsmed, Inc. (INSM) Coverage Initiated by Analysts at Robert W. Baird - July 10 at 7:14 PM logoInsmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages - July 7 at 10:50 AM logoCystic Fibrosis Therapeutics Pipeline H1 2017 Research Report ... - PR Newswire (press release) - June 30 at 8:04 PM logoInsmed, Inc. (INSM) Expected to Post Earnings of -$0.63 Per Share - June 30 at 11:23 AM logoOptions Traders Expect Huge Moves in Insmed (INSM) Stock - June 27 at 6:06 PM logoBidaskClub Upgrades Insmed, Inc. (INSM) to "Hold" - June 23 at 8:20 PM logoInsmed to Present at the JMP Securities Life Sciences Conference - June 13 at 10:52 AM logoInsmed, Inc. (INSM) Receives Consensus Rating of "Buy" from Analysts - June 12 at 11:24 AM logoInsmed Incorporated (INSM) Stock Rating Reaffirmed by Citigroup Inc. - June 11 at 7:40 PM logoInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release) - June 8 at 6:55 PM logoInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 8 at 6:55 PM logo-$0.63 Earnings Per Share Expected for Insmed Incorporated (INSM) This Quarter - June 6 at 12:30 AM logoInsmed Incorporated (INSM) Upgraded to Hold at ValuEngine - June 4 at 10:38 AM logoInsmed Incorporated (INSM) General Counsel Acquires $151,400.00 in Stock - June 1 at 8:14 PM logoForm 8-K INSMED Inc For: May 15 - - May 20 at 5:44 PM logoBRIEF-Insmed Inc files for potential stock shelf offering - May 19 at 5:39 PM logoInsmed Announces Key Additions to its Executive Management Team - GlobeNewswire (press release) - May 16 at 10:50 PM logo-$0.62 EPS Expected for Insmed Incorporated (INSM) This Quarter - May 10 at 8:36 AM logoQ2 2017 Earnings Forecast for Insmed Incorporated Issued By Leerink Swann (INSM) - May 8 at 8:21 AM logoInsmed Incorporated (INSM) Releases Earnings Results, Hits Expectations - May 5 at 11:53 PM logoBest Biotech Stocks For Capital Gains In The Next 3 Months - May 4 at 6:07 PM logoBRIEF-Insmed reports Q1 loss per share $0.60 - May 4 at 6:07 PM logoEdited Transcript of INSM earnings conference call or presentation 3-May-17 12:30pm GMT - May 4 at 6:07 PM logoForm 8-K INSMED Inc For: May 03 - - May 4 at 12:41 AM logoInvestor Network: Insmed Incorporated to Host Earnings Call - May 4 at 12:41 AM logoInsmed Reports First Quarter 2017 Financial Results and Provides Business Update - May 4 at 12:41 AM logoInsmed reports 1Q loss - May 4 at 12:41 AM logoInsmed (INSM) Given Coverage Optimism Score of 0.44 - May 3 at 11:20 AM logoInsmed Incorporated (INSM) Given Buy Rating at Stifel Nicolaus - May 1 at 3:02 PM logoInsmed (INSM) Getting Positive News Coverage, Analysis Shows - April 30 at 10:51 AM logoImplied Volatility Surging for Insmed (INSM) Stock Options - Nasdaq - April 29 at 9:11 AM logoImplied Volatility Surging for Insmed (INSM) Stock Options - April 28 at 10:01 AM logoInsmed (INSM) Earning Favorable Press Coverage, Report Finds - April 27 at 9:32 PM logoInsmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017 - Yahoo Finance - April 27 at 8:48 AM



Insmed (INSM) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff